FDA Explains Reason for Caution With Johnson & Johnson Vaccine

Dr. Peter Marks, Director, FDA Center for Biologics Evaluation and Research, explains why the FDA recommended a pause in the administration of the Johnson & Johnson vaccine despite the appearance of blood clots being so rare.